Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)

BMC Immunology

Volumn 16, Issue 1, 2015, Pages

  Hardcastle, Sharni Lee ^a   Brenu, Ekua Weba ^a   Johnston, Samantha ^a   Nguyen, Thao ^a   Huth, Teilah ^a   Wong, Naomi ^a   Ramos, Sandra ^a   Staines, Donald ^a   Marshall Gradisnik, Sonya ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

CD8+T Cell; Chronic fatigue syndrome; Natural killer cell; Receptors

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD150 ANTIGEN; CD16 ANTIGEN; CD18 ANTIGEN; CD45RA ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN P 15095; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL5; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR; T LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INNATE IMMUNITY; MALE; MONOCYTE; NEUTROPHIL; PROTEIN EXPRESSION; B LYMPHOCYTE; BLOOD; BLOOD CELL COUNT; CELL ADHESION; CELL SEPARATION; CYTOTOXICITY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NATURAL KILLER CELL; PATHOLOGY; PHENOTYPE;

ADULT; B-LYMPHOCYTES, REGULATORY; BLOOD CELL COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FATIGUE SYNDROME, CHRONIC; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; PHENOTYPE; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, IMMUNOLOGIC; RECEPTORS, KIR2DL5;

EID: 84930649109     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/s12865-015-0101-4     Document Type: Article

References (61)

1. Maes M, Twisk FN, Kubera M, Ringel K. Evidence for inflammation and activation of cell-mediated immunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin. J Affect Disord. 2012;136(3):933-9.
2. Seide A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Increased CD56 natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol. 1996;78(1):83-5.
3. Blanca IR, Bere EW, Young HA, Ortaldo JR. Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: role of memory B cells and CD5+ B cells. J Immunol. 2001;167(11):6132-9.
4. Schepis D, Gunnarsson I, Eloranta ML, Lampa J, Jacobson SH, Kärre K, et al. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology. 2009;126(1):140-6.
5. Hardcastle S, Brenu E, Johnston S, Nguyen T, Huth T, Kaur M. Analysis of the relationship between immune dysfunction and symptom severity in patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). J Clin Cell Immunol. 2014;5(190):2.
6. Landay A, Lennette E, Jessop C, Levy J. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet. 1991;338(8769):707-12.
7. Brenu, Hardcastle, Atkinson G, van Driel M, Kreijkamp-Kaspers S, Ashton K, et al.: Natural killer cells in patients with severe chronic fatigue syndrome. Autoimmunity Highlights 2013;4(3):1-12.
8. Brenu EW, Staines DR, Baskurt OK, Ashton KJ, Ramos SB, Christy RM, et al. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med. 2010;8(1):1.
9. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2012;10:88.
10. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2011;9:81.
11. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28(6):1403-10.
12. Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herberman RB. Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol. 1998;88(1):96-104.
13. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis. 1994;18(Supplement 1):S157-9.
14. Patarca-Montero R, Antoni M, Fletcher MA, Klimas NG. Cytokine and other immunologic markers in chronic fatigue syndrome and their relation to neuropsychological factors. Appl Neuropsychol. 2001;8(1):51-64.
15. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis. 1994;18(Supplement 1):S136-41.
16. Brenu E, Johnston S, Hardcastle S, Huth T, Fuller K, Ramos S, et al. Immune abnormalities in patients meeting new diagnostic criteria for chronic fatigue syndrome/Myalgic Encephalomyelitis. J Mol Biomark Diagn. 2013;4(152.10):4172.
17. Brenu EW, Huth TK, Hardcastle SL, Fuller K, Kaur M, Johnston S, et al. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol. 2013;26:dxt068.
18. Brenu EW, van Driel M, Staines DR, Kreijkamp-Kaspers S, Hardcastle SL, Marshall-Gradisnik SM. The effects of influenza vaccination on immune function in patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. International J Clinical Med. 2012;3:544.
19. Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, Peterson D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987;139(10):3306-13.
20. Maher KJ, Klimas NG, Fletcher MA. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol. 2005;142(3):505-11.
21. Patarca R, Klimas NG, Garcia MN, Walters MJ, Dombroski D, Pons H, et al. Dysregulated expression of soluble immune mediator receptors in a subset of patients with chronic fatigue syndrome: cross-sectional categorization of patients by immune status. J Chronic Fatigue Syndrome. 1995;1(1):81-96.
22. Tirelli U, Marotta G, Improta S, Pinto A. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol. 1994;40(6):601-8.
23. Aoki T, Miyakoshi H, Usuda Y, Herberman RB. Low NK syndrome and its relationship to chronic fatigue syndrome. Clin Immunol Immunopathol. 1993;69(3):253-65.
24. Huth T, Brenu E, Nguyen T, Hardcastle S, Johnston S. Characterization of natural killer cell phenotypes in chronic fatigue Syndrome/Myalgic Encephalomyelitis. J Clin Cell Immunol. 2014;5(223):2.
25. Brenu EW, Ashton KJ, van Driel M, Staines DR, Peterson D, Atkinson GM, et al. Cytotoxic lymphocyte microRNAs as prospective biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis. J Affect Disord. 2012;141(2):261-9.
26. Saiki T, Kawai T, Morita K, Ohta M, Saito T, Rokutan K, et al. Identification of marker genes for differential diagnosis of chronic fatigue syndrome. Mol Med. 2008;14(9-10):599.
27. Baraniuk JN, Adewuyi O, Merck SJ, Ali M, Ravindran MK, Timbol CR, et al. A Chronic Fatigue Syndrome (CFS) severity score based on case designation criteria. Am J Transl Res. 2013;5(1):53-68.
28. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270(4):327-38.
29. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121(12):953-9.
30. Zaturenskaya M, Jason LA, Torres-Harding S, Tryon WW. Subgrouping in chronic fatigue syndrome based on actigraphy and illness severity. Open Biology J. 2009;2:20-6.
31. Jason LA, Corradi K, Torres-Harding S, Taylor RR, King C. Chronic fatigue syndrome: the need for subtypes. Neuropsychol Rev. 2005;15(1):29-58.
32. Wiborg JF, van der Werf S, Prins JB, Bleijenberg G. Being homebound with chronic fatigue syndrome: a multidimensional comparison with outpatients. Psychiatry Res. 2010;177(1):246-9.
33. Lloyd AR, Wakefield D, Boughton C, Dwyer J. Immunological abnormalities in the chronic fatigue syndrome. Med J Aust. 1989;151(3):122.
34. Bansal A, Bradley A, Bishop K, Kiani-Alikhan S, Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun. 2012;26(1):24-31.
35. Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, et al. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One. 2011;6(10):e26358.
36. Klimas NG, Broderick G, Fletcher MA. Biomarkers for chronic fatigue. Brain Behav Immun. 2012;26(8):1202-10.
37. Sidorenko SP, Clark EA. The dual-function CD150 receptor subfamily: the viral attraction. Nat Immunol. 2003;4(1):19-24.
38. Lanier LL. On guard-activating NK cell receptors. Nat Immunol. 2001;2(1):23-7.
39. Wang N, Morra M, Wu C, Gullo C, Howie D, Coyle T, et al. CD150 is a member of a family of genes that encode glycoproteins on the surface of hematopoietic cells. Immunogenetics. 2001;53(5):382-94.
40. Veillette A. NK cell regulation by SLAM family receptors and SAP related adapters. Immunol Rev. 2006;214(1):22-34.
41. Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, et al. Human natural killer cell receptors and co receptors. Immunol Rev. 2001;181(1):203-14.
42. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458-65.
43. Anane LH, Edwards KM, Burns VE, Zanten JJ, Drayson MT, Bosch JA. Phenotypic characterization of γδ T cells mobilized in response to acute psychological stress. Brain Behav Immun. 2010;24(4):608-14.
44. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-63.
45. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14(1):24-35.
46. Henson SM, Akbar AN. KLRG1-more than a marker for T cell senescence. Age. 2009;31(4):285-91.
47. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008;10(1):29-37.
48. Curriu M, Carrillo J, Massanella M, Rigau J, Alegre J, Puig J, et al. Screening NK-B-and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. J Transl Med. 2013;11:68.
49. Estefanía E, Flores R, Gómez-Lozano N, Aguilar H, López-Botet M, Vilches C. Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. J Immunol. 2007;178(7):4402-10.
50. Cisneros E, Moraru M, Gómez-Lozano N, López-Botet M, Vilches C. KIR2DL5: an orphan inhibitory receptor displaying complex patterns of polymorphism and expression. Front Immunol. 2012;3.
51. Vilches C, Rajalingam R, Uhrberg M, Gardiner CM, Young NT, Parham P. KIR2DL5, a novel killer-cell receptor with a D0-D2 configuration of Ig-like domains. J Immunol. 2000;164(11):5797-804.
52. Hurchla MA, Sedy JR, Murphy KM. Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation. J Immunol. 2007;178(10):6073-82.
53. Nielsen N, Ødum N, Ursø B, Lanier LL, Spee P. Cytotoxicity of CD56bright NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS One. 2012;7(2), e31959.
54. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev. 2006;214(1):73-91.
55. Lima M, Almeida J, dos Anjos TM, Queirós ML, Justiça B, Orfão A. The "< i > ex Vivo" Patterns of CD2/CD7, CD57/CD11c, CD38/CD11b, CD45RA/CD45RO, and CD11a/HLA-DR Expression Identify Acute/Early and Chronic/Late NK-Cell Activation States. Blood Cell Mol Dis. 2002;28(2):181-90.
56. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005;5(3):243-51.
57. Bryant PA, Trinder J, Curtis N. Sick and tired: does sleep have a vital role in the immune system? Nat Rev Immunol. 2004;4(6):457-67.
58. Üstün TB. Measuring health and disability: Manual for WHO disability assessment schedule WHODAS 2.0. In: World Health Organization. 2010.
59. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. In: Medical care. 1992. p. 473-83.
60. Montoya CJ, Pollard D, Martinson J, Kumari K, Wasserfall C, Mulder CB, et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell clonotypic monoclonal antibody, 6B11. Immunology. 2007;122(1):1-14.
61. Aguinis H, Gottfredson RK, Joo H. Best-practice recommendations for defining, identifying, and handling outliers. Organ Res Methods. 2013;16(2):270-301.